SALAGEN (pilocarpine hydrochloride) by Orasis Pharmaceuticals is clinical pharmacology: pharmacodynamics: pilocarpine is a cholinergic parasympathomimetic agent exerting a broad spectrum of pharmacologic effects with predominant muscarinic action. First approved in 1994.
Drug data last refreshed 8h ago · AI intelligence enriched 1w ago
SALAGEN is an oral cholinergic parasympathomimetic agent (pilocarpine hydrochloride) approved in 1994 for stimulating salivary and lacrimal gland secretion. It works by acting as a broad-spectrum muscarinic agonist, increasing exocrine gland output including sweat, salivary, lacrimal, gastric, pancreatic, and intestinal secretions. The drug is indicated primarily for xerostomia (dry mouth) in head and neck cancer patients post-radiation and for dry mouth and dry eye symptoms in Sjögren's syndrome patients.
Mature niche product with declining volume and small market footprint; limited growth opportunity and likely team consolidation ahead.
CLINICAL PHARMACOLOGY: Pharmacodynamics: Pilocarpine is a cholinergic parasympathomimetic agent exerting a broad spectrum of pharmacologic effects with predominant muscarinic action. Pilocarpine, in appropriate dosage, can increase secretion by the exocrine glands. The sweat, salivary, lacrimal,…
Worked on SALAGEN at Orasis Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moSALAGEN offers limited career advancement opportunities due to its mature, declining lifecycle and minimal job postings in the market. Roles on this product are primarily focused on defending market share and managing the commercial wind-down rather than driving growth or innovation.